Bank of Hawaii lowered its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 17.9% during the fourth quarter, HoldingsChannel reports. The firm owned 38,939 shares of the pharmaceutical company’s stock after selling 8,514 shares during the quarter. Bank of Hawaii’s holdings in GlaxoSmithKline were worth $1,381,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Field & Main Bank purchased a new position in shares of GlaxoSmithKline during the fourth quarter worth about $132,000. First Dallas Securities Inc. purchased a new position in shares of GlaxoSmithKline during the fourth quarter worth about $142,000. Wealthcare Advisory Partners LLC grew its holdings in shares of GlaxoSmithKline by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares during the last quarter. Waldron LP purchased a new position in shares of GlaxoSmithKline during the third quarter worth about $203,000. Finally, Belpointe Asset Management LLC purchased a new position in shares of GlaxoSmithKline during the third quarter worth about $204,000. Institutional investors and hedge funds own 9.17% of the company’s stock.
A number of equities analysts recently issued reports on GSK shares. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, January 2nd. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and raised their price target for the stock from $35.04 to $35.85 in a report on Monday, November 27th. Barclays raised GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 16th. Argus lowered their price target on GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. Finally, Cowen set a $38.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $38.97.
Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $36.84 on Friday. GlaxoSmithKline plc has a twelve month low of $34.52 and a twelve month high of $44.53. The firm has a market capitalization of $89,740.00, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 2.26 and a beta of 0.98. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.39.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The company had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. equities research analysts forecast that GlaxoSmithKline plc will post 2.89 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be issued a $0.633 dividend. This represents a $2.53 dividend on an annualized basis and a yield of 6.87%. The ex-dividend date of this dividend is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s payout ratio is currently 169.80%.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/25/glaxosmithkline-plc-gsk-shares-sold-by-bank-of-hawaii.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.